Hydreight's Oct. 22 cash at $18.7-million

Executive Summary

• Hydreight Technologies Inc. reported strong operational growth for the third quarter of 2025, highlighted by a ranking of #25 on Deloitte's 2025 Technology Fast 50 (Canada) and significant increases in product orders and nurse network sign-ups.
• The company closed an oversubscribed $11.5-million convertible debenture financing on September 4, 2025, bringing its cash position to approximately $18.7 million as of October 22, 2025.
• Key operational metrics include a 72% year-over-year increase in pharmacy orders (excluding VSDHOne) and a 63% year-over-year increase in nurse sign-ups for the first nine months of 2025, driven by demand in GLP-1 weight management and other wellness verticals.

Key Details

• Deloitte Recognition: Ranked No. 25 on Deloitte's 2025 Technology Fast 50 (Canada) based on revenue growth from 2021 to 2024; previously ranked No. 56 on Deloitte's 2024 Technology Fast 500 (U.S.).
• TSX Venture Recognition: Recognized on the 2025 list as a Top 50 TSX Venture Exchange company for 2024.
• Award Finalist Status: Selected as a finalist for Company of the Year -- Scale Award at the B.C. Tech Association's 2025 Technology Impact Awards (TIAs) and announced as a Pacific region finalist for the EY Entrepreneur of the Year Canada 2025 Awards.
• Q3 2025 Product Orders: Processed approximately 295,000 VSDHOne product orders between July and September 2025.
• Nurse Network Growth:
  • 198 new nurse sign-ups between July and September 2025 (up 49% year-over-year from 133 in the same period last year).
  • 593 total sign-ups in the first nine months of 2025 versus 364 in 2024 (approximately 63% year-over-year increase).
• Pharmacy Order Growth: Pharmacy orders (excluding VSDHOne) increased approximately 72% year-over-year.
• Financing Details:
  • Closed an oversubscribed $11.5-million convertible debenture financing on September 4, 2025.
  • Cash position stood at approximately $18.7 million as of October 22, 2025.
• Infrastructure & Technology:
  • Integration of 503A/503B pharmacy partners to increase capacity, fulfillment speed, and margin potential.
  • Upcoming release of VSDHOne V2, an enhanced platform version designed for greater automation, scalability, and modular functionality.
• Strategic Focus Areas:
  • GLP-1 & D2C: Continuing national rollout of Dr. Franklin Joseph's GLP-1 program and direct-to-consumer wellness offerings.
  • M&A Pipeline: Actively evaluating profitable multistate wellness and digital health operators for acquisition to scale nationally through VSDHOne.
• Analyst Coverage: Reports initiated by Maxim Group and Beacon Securities.
• Upcoming Investor Conferences:
  • CEM Muskoka Capital Event: Sept. 26–28, 2025.
  • Smallcap Discoveries Investor Event: Sept. 29–30, 2025 (Vancouver, B.C.).
  • Planet MicroCap Showcase: Oct. 22–23, 2025 (Toronto, Ont.). Presentation scheduled for Oct. 22 at 5:30 p.m. ET; one-on-one meetings on Oct. 22 and 23.

Notable Quotes

• "Hydreight's recognition by Deloitte as one of Canada's fastest-growing technology companies is a validation of our model and execution. Our performance from July to September demonstrates the strength and scalability of our compliant health care infrastructure. With approximately $18.7-million in cash, we're well positioned to accelerate growth across our GLP-1, D2C and pharmacy network initiatives while continuing to execute profitably and responsibly." — Shane Madden, Chief Executive Officer